2 Underrated Weight Loss Stocks to Buy Now
Investors who want to capitalize on the growing weight loss market might be tempted to turn to the current leaders in the field, Eli Lilly and Novo Nordisk. Both companies are worth serious consideration, in my view, but other drugmakers could also offer investors exposure to this area while having more diversified portfolios. Some investors might be more attracted to this value proposition. That said, here are two companies quietly making progress in the weight-loss market that may be worth investing in today: (NASDAQ: REGN) and (OTC: RHHBY).
Image source: Getty Images.
Last year, Regeneron reported strong phase 2 results for one of its leading weight-loss candidates, trevogrumab. One thing to note about this product is that it is being developed to help minimize muscle loss in patients taking GLP-1 medicines. In the mid-stage trial, though about 33% of the weight loss in patients taking semaglutide (the generic name for Wegovy) was due to lean mass loss, trevogrumab was able to avert about half of that lean mass loss.
Source Fool.com
Regeneron Pharmaceuticals Inc. Aktie
Volle Unterstützung für Regeneron Pharmaceuticals Inc.: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Für Regeneron Pharmaceuticals Inc. ergibt sich mit einem Kursziel von 731 € ein leicht positives Potenzial gegenüber dem aktuellen Kurs von 714.1 €.
